1. Singapore Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Cordlife Group Limited

Cordlife Group Limited

0.13
USD
-0.02
(-14.74%)
-0.03EPS
38.34MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.15
0.19
0.22
0.23
0.23
0.27
0.24
0.23
0.22
0.22
0.22
0.11
0.15
0.14
Basic EPS, GAAP
0.06
0.12
0.12
0.05
-0.01
0.01
0.03
0.03
0.02
0.02
0.01
-0.07
-0.05
-0.04
Free Cash Flow per Basic Share
0.03
0.01
-0.02
-0.04
0.01
0.03
0.04
0.06
0.03
0.02
0.03
-0.06
-0.01
- -
Dividend per Share
0.03
0.02
0.02
0.14
- -
- -
- -
0.01
0.01
0.01
- -
- -
- -
- -
Book Value per Share
0.33
0.53
0.63
0.5
0.5
0.48
0.51
0.52
0.53
0.52
0.53
0.46
0.41
0.39
Tangible Book Value per Share
0.33
0.52
0.62
0.45
0.45
0.31
0.38
0.4
0.41
0.4
0.41
0.34
0.3
0.28
Basic Weighted Avg Shares
233
257
260
259
259
253
254
254
255
256
256
256
256
256
Sales/Revenue/Turnover
35
49
58
60
60
68
62
59
57
55
56
28
39
37
Operating Margin (%)
21.13
17.67
9.51
1.76
-0.33
4.73
-5.42
7.58
7.06
2.22
-1.41
-87.8
-38.19
-32.35
Depreciation Expense
1
2
2
3
3
3
4
4
4
4
4
4
4
4
Net Income, GAAP
13
31
32
12
-3
3
6
7
6
5
4
-19
-13
-11
Effective Tax Rate (%)
7.38
4.63
3.44
5.7
- -
26.4
20.47
13.26
12.47
11.21
16.25
- -
- -
- -
Profit Margin (%)
38.86
62.18
56.37
20.68
-4.29
4.79
10.51
11.1
10.83
8.86
6.32
-68.3
-32.53
-28.93
Working Capital
10
42
30
131
67
- -
57
77
76
87
80
66
56
54
LT Debt
6
8
125
76
7
4
5
6
1
1
2
1
1
1
Total Equity
78
141
162
133
130
121
129
133
137
134
136
118
104
100
Return on Invested Capital (%)
11.81
7.27
2.65
1.1
- -
2.34
4.56
4.47
4.1
2.84
1.7
- -
- -
- -
Return on Capital (%)
17.18
25.95
16.8
6.91
- -
2.67
5.12
4.94
4.5
3.64
2.69
- -
- -
- -
Return on Common Equity (%)
18.13
27.86
21.36
8.41
-1.97
2.6
5.17
4.99
4.55
3.61
2.62
-14.9
-11.36
-10.1

Capital Structure

SGD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
256
256
256
Market Capitalization
23
23
50

Working Capital

SGD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
85
79
84
Cash, Cash Equivalents & STI
51
45
49
Accounts Receivable, Net
25
25
26
Inventories
1
1
1
Total Current Liabilities
29
31
30
Payables & Accruals
- -
- -
- -
ST Debt
1
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

SGD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.98%
-4.52%
-11.8%
Free Cash Flow
-23.65%
-89.79%
-90.38%
Net Income, GAAP
-103.47%
-144.72%
-33.06%
Sales/Revenue/Turnover
-1.14%
-3.08%
40.53%
Total Cash Common Dividend
- -
- -
-2.7%

Quarterly Revenue

SGD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
10
8
28
2025
10
10
10
9
39
2026
9
8
- -
- -
- -

Quarterly Earnings Per Share

SGD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
-0.01
-0.02
-0.07
2025
-0.01
-0.01
-0.01
-0.02
-0.05
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

SGD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xiaoling Chen
Full Time Employees
596
Sector
Health services
Industry
Medical/Nursing services
Address
1 Yishun Industrial Street 1 Singapore CE Singapore 768160
IPO Date
Mar 29, 2012
Website
cordlife.com
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Cordlife Group Limited (SGX: P8A), founded in 2001 and headquartered in Singapore, operates Asia's largest network of private cord blood banks with full stem cell processing and storage facilities in six key markets including Singapore, Hong Kong, Indonesia, the Philippines, India and Malaysia; through its majority-owned subsidiary Stemlife Berhad in Malaysia, the Group holds an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife; it provides cord blood banking services involving collection, processing, testing and cryopreservation of haematopoietic stem cells; cord lining banking services, including mesenchymal stem cells and epithelial stem cells under exclusive license from CellResearch Corporation Pte Ltd; cord tissue banking focused on Wharton's Jelly and mesenchymal stem cells using proprietary technology; placenta banking; peripheral blood stem cell banking for haematopoietic stem cells; gut microbiome banking in partnership with AMILI Pte Ltd; corneal lenticule banking; and a comprehensive suite of diagnostics services such as non-invasive prenatal testing (NIPT) with expanded panels covering microdeletion syndromes, newborn genetic and metabolic screening (including Bebegene detecting over 100 conditions), paediatric vision screening (Eyescreen), ear screening (Earscreen), allergen testing, genetic talent testing, preimplantation genetic screening, endometrial receptivity testing, lifestyle genetic tests for sports, skin, diet and health, and digital healthcare via the Moms Up app; the Group serves families across 10 markets including Bangladesh, Myanmar, Vietnam, Macau, Brunei and Cambodia, with extensive transplant experience including 77 cord blood releases to 21 healthcare institutions in 10 countries and 21 cord lining, cord tissue and mesenchymal stem cell releases; its facilities hold multiple accreditations such as AABB, FACT, CAP, NABL, ISO and regulatory approvals from bodies like Singapore's Ministry of Health, India's DCGI and others. Recent developments include approval from Singapore's Ministry of Health in August 2024 to resume cord blood banking services with restrictions following prior storage issues; unveiling of an enhanced processing and storage facility in Singapore in September 2024 featuring AXP II automated systems and real-time cryogenic monitoring; reaccreditations for overseas operations and service expansions in July 2024; accelerated recruitment of lab and technical staff in May 2024 to strengthen core processes; partnership with Shandong Qilu Stemcell Engineering Co Ltd to enhance efficiency and service quality; focus on mesenchymal stem cell secretome therapies for osteoarthritis; ISO recertification and AABB reaccreditation for Cordlife Philippines in August 2025; and a voluntary conditional cash partial offer announced in May 2025.